Orexo is a Swedish pharmaceutical company that develops improved pharmaceuticals based on innovative formulation technologies that meet large medical needs. Through presence its in the US market, drugs and digital therapies are commercialized to treat opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with partners.
History
The company was founded in 1995 and their first product Diabact UBT, a breath test for diagnosing the causative agent of stomach ulcers (Helicobacter pylori), was introduced in 2000. In 2003, the company adopted the name Orexo and in 2005 the company was listed on the Stockholm Stock Exchange.[4]
In 2008 the development of Abstral, a drug for the treatment of breakthrough cancer, was finalized. Abstral was the first product developed based on Orexo´s world-leading sublingual platform.
In 2010, through a right issue, Novo A/S became the largest shareholder in Orexo. With the investment from Novo A/S, the Board of Directors reviewed the strategy and created a vision of establishing a commercial business in the US.
In 2013, Orexo established a commercial subsidiary in the US and launched ZUBSOLV, a drug for the treatment of opioid use disorder.
In 2018, the company won a multiyear patent battle against the generic company